MC

445.15

+0.33%↑

SANES

6.915

+0.12%↑

ALV

341.6

-0.23%↓

BNP

75.89

-0.05%↓

BBVA

12.755

-0.7%↓

MC

445.15

+0.33%↑

SANES

6.915

+0.12%↑

ALV

341.6

-0.23%↓

BNP

75.89

-0.05%↓

BBVA

12.755

-0.7%↓

MC

445.15

+0.33%↑

SANES

6.915

+0.12%↑

ALV

341.6

-0.23%↓

BNP

75.89

-0.05%↓

BBVA

12.755

-0.7%↓

MC

445.15

+0.33%↑

SANES

6.915

+0.12%↑

ALV

341.6

-0.23%↓

BNP

75.89

-0.05%↓

BBVA

12.755

-0.7%↓

MC

445.15

+0.33%↑

SANES

6.915

+0.12%↑

ALV

341.6

-0.23%↓

BNP

75.89

-0.05%↓

BBVA

12.755

-0.7%↓

Search

Sartorius Stedim Biotech.

Abierto

SectorFinanzas

205.8 0.83

Resumen

Variación precio

24h

Actual

Mínimo

201.1

Máximo

207.6

Métricas clave

By Trading Economics

Ingresos

75M

115M

Ventas

-6.7M

745M

P/B

Media del Sector

92.346

24.617

BPA

1.16

Rentabilidad por dividendo

0.34

Margen de beneficios

15.498

Empleados

9,961

EBITDA

124M

256M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+15.15% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.34%

4.23%

Próximas Ganancias

22 jul 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

2.4B

19B

Apertura anterior

204.97

Cierre anterior

205.8

Noticias sobre sentimiento de mercado

By Acuity

39%

61%

141 / 538 Clasificación en Finance

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Sartorius Stedim Biotech. Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

26 jun 2025, 23:49 UTC

Ganancias

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26 jun 2025, 22:19 UTC

Adquisiciones, fusiones, absorciones

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26 jun 2025, 21:30 UTC

Ganancias

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26 jun 2025, 21:07 UTC

Ganancias

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26 jun 2025, 23:49 UTC

Charlas de Mercado

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26 jun 2025, 23:39 UTC

Charlas de Mercado

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26 jun 2025, 23:34 UTC

Adquisiciones, fusiones, absorciones

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26 jun 2025, 23:33 UTC

Adquisiciones, fusiones, absorciones

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26 jun 2025, 23:32 UTC

Adquisiciones, fusiones, absorciones

Wesfarmers Will No Longer Receive Earnings From BWP Management

26 jun 2025, 23:32 UTC

Adquisiciones, fusiones, absorciones

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26 jun 2025, 23:31 UTC

Adquisiciones, fusiones, absorciones

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26 jun 2025, 23:31 UTC

Adquisiciones, fusiones, absorciones

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26 jun 2025, 23:30 UTC

Adquisiciones, fusiones, absorciones

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26 jun 2025, 23:29 UTC

Adquisiciones, fusiones, absorciones

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26 jun 2025, 23:19 UTC

Adquisiciones, fusiones, absorciones

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26 jun 2025, 22:06 UTC

Ganancias

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 jun 2025, 21:15 UTC

Ganancias

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26 jun 2025, 21:07 UTC

Adquisiciones, fusiones, absorciones

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26 jun 2025, 21:07 UTC

Adquisiciones, fusiones, absorciones

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26 jun 2025, 21:07 UTC

Adquisiciones, fusiones, absorciones

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26 jun 2025, 21:07 UTC

Ganancias

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 jun 2025, 21:06 UTC

Adquisiciones, fusiones, absorciones

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26 jun 2025, 21:06 UTC

Adquisiciones, fusiones, absorciones

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26 jun 2025, 21:06 UTC

Charlas de Mercado

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26 jun 2025, 21:05 UTC

Adquisiciones, fusiones, absorciones

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 jun 2025, 21:05 UTC

Adquisiciones, fusiones, absorciones

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 jun 2025, 20:52 UTC

Ganancias

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26 jun 2025, 20:51 UTC

Ganancias

Correct: Nike 4Q Net $211M, Not $200M >NKE

26 jun 2025, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

26 jun 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Sartorius Stedim Biotech. previsión

Precio Objetivo

By TipRanks

15.15% repunte

Estimación a 12 Meses

Media 234.67 EUR  15.15%

Máximo 250 EUR

Mínimo 210 EUR

De acuerdo con 9 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Sartorius Stedim Biotech. Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

9 ratings

5

Comprar

4

Mantener

0

Vender

Puntuación técnica

By Trading Central

202.7 / 211.7Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

Strong Bullish Evidence

Sentimiento

By Acuity

141 / 538 Clasificación en Finanzas

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.